

MaÅ,gorzata Walus-Miarka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/872694/publications.pdf>

Version: 2024-02-01

11
papers

252
citations

1478505

6
h-index

1474206

9
g-index

11
all docs

11
docs citations

11
times ranked

555
citing authors

#	ARTICLE	IF	CITATIONS
1	Refinement of Variant Selection for the LDL Cholesterol Genetic Risk Score in the Diagnosis of the Polygenic Form of Clinical Familial Hypercholesterolemia and Replication in Samples from 6 Countries. <i>Clinical Chemistry</i> , 2015, 61, 231-238.	3.2	166
2	The genetic spectrum of familial hypercholesterolemia in south-eastern Poland. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 48-53.	3.4	26
3	Nonalcoholic fatty liver disease is associated with low HDL cholesterol and coronary angioplasty in patients with type 2 diabetes. <i>Medical Science Monitor</i> , 2013, 19, 1167-1172.	1.1	24
4	Carotid Plaques Correlates in Patients With Familial Hypercholesterolemia. <i>Angiology</i> , 2016, 67, 471-477.	1.8	10
5	Intima-media thickness correlates with features of metabolic syndrome in young people with a clinical diagnosis of familial hypercholesterolaemia. <i>Kardiologia Polska</i> , 2013, 71, 566-572.	0.6	9
6	Carotid artery plaques – Are risk factors the same in men and women with familial hypercholesterolemia?. <i>International Journal of Cardiology</i> , 2017, 244, 290-295.	1.7	7
7	Serum pentraxin 3 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 499-505.	0.4	7
8	Correlates of pentraxin 3 serum concentration in men and women with type 2 diabetes. <i>Innate Immunity</i> , 2020, 26, 351-357.	2.4	2
9	Serum PCSK9 Correlates with PTX3 and Apolipoproteins B, A1, and C3 Concentrations in Patients with Type 2 Diabetes. <i>Cardiovascular Therapeutics</i> , 2021, 2021, 1-9.	2.5	1
10	Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. Authors' reply. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 648-650.	0.4	0
11	Effectiveness and safety of PCSK9 inhibitor therapy in patients with familial hypercholesterolemia within a therapeutic program in Poland: Preliminary multicenter data. <i>Cardiology Journal</i> , 2022, 29, 62-71.	1.2	0